Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
100 hedge funds and large institutions have $218M invested in Cymabay Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 18 closing their positions.
66% more call options, than puts
Call options by funds: $865K | Put options by funds: $520K
17% more capital invested
Capital invested by funds: $186M → $218M (+$32M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less funds holding
Funds holding: 106 → 100 (-6)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.87M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$2.14M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$1.22M |
| 4 |
Two Sigma Advisers
New York
|
+$834K |
| 5 |
Walleye Capital
New York
|
+$790K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.32M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.03M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$948K |
| 4 |
Morgan Stanley
New York
|
-$883K |
| 5 |
PCM
Pinz Capital Management
New York
|
-$683K |
CBAY Hedge Fund Activity: Q3 2022 in Review
100 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2022, worth a combined $218M — up 17% from $186M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CBAY and 12 opened new positions — a net loss of 6 holders — while 30 trimmed existing stakes and 18 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $2.87M. The largest seller was Millennium Management, cutting an estimated $5.32M.
- 100 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2022, down from 106 in Q2 2022.
- Funds reported $218M of Cymabay Therapeutics stock for Q3 2022, up 17% quarter-over-quarter.
- 12 funds opened new Cymabay Therapeutics positions in Q3 2022 and 18 closed out, a net change of -6 holders.
- The largest Cymabay Therapeutics buyer in Q3 2022 was Great Point Partners, an estimated $2.87M added.
- The largest Cymabay Therapeutics seller in Q3 2022 was Millennium Management, an estimated $5.32M sold.
Based on aggregated 13F filings for Q3 2022.